APGE | Ticker Profile - Titan Protect

APGE

Apogee Therapeutics, Inc.

Healthcare · Biotechnology · NGM

$86.92

Data: 2026-05-28

✗ ETHICAL FAIL

Unknown MOAT

MODERATE

Data Confidence: 71.4%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$5.9B

Total market value of the company

Trailing P/E

N/A

Forward P/E

-15.01

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

0.0%

How much profit the company keeps from each dollar of revenue

ROE

-28.5%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$120.00

+38% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 16 analysts covering this stock

About Apogee Therapeutics, Inc.

Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of atopic dermatitis, which is in phase 2 clinical trials; and for the treatment of asthma and eosinophilic esophagitis which is in phase 1 clinical trial. It also develops APG279 which is in phase 1 clinical trial for the treatment of atopic dermatitis; APG273 which is in phase 1 clinical trial for the treatment of asthma and chronic obstructive pulmonary disease; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

https://www.apogeetherapeutics.com

Country: United States Employees: 261 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% N/A

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

0.752

Good returns relative to risk taken

Kelly Fraction

0.0608

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

0.595

Acceptable balance between returns and drawdown risk

Annual Return

31.5%

Historical annualised return based on price data

Max Drawdown

-52.9%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.69

Less volatile than the market — more defensive

52W High

$95.32

9% below the year high

52W Low

$34.34

153% above the year low

Avg Volume

929,050

Average daily shares traded — higher means easier to buy and sell

Short Ratio

14.6

Days it would take all short sellers to cover — higher means more crowded

Short % Float

19.6%

Elevated short interest — bears are positioned against this

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-4.33

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

0.64

Moderate leverage — manageable

Current Ratio

32.59

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

32.39

Like current ratio but excludes inventory — stricter test

Gross Margin

0.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

0.0%

Profit from core operations before interest and tax

Free Cash Flow

$-142,579,376

Negative — the business is spending more than it generates

Revenue (TTM)

N/A

Total revenue over the last 12 months

Net Income

$-274,615,008

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$160.00

Target Median

$120.00

Target Low

$82.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go